Hematology Drugs Global Market Report 2018

1. Hematology Drugs Global Market Report 2018 Including: Blood Products; Anemia And Other Blood Disorder Drugs Covering: Novo Nordisk A/S, Shire Plc, Bayer AG, Daiichi Sankyo Company, Limited, Biogen Inc. Feb 2018

2. Reasons to Purchase • Outperform competitors using accurate up to date demand-side dynamics information. • Identify growth segments for investment. • Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market. • Create regional and country strategies on the basis of local data and analysis. • Stay abreast of the latest customer and market research findings • Benchmark performance against key competitors. • Develop strategies based on likely future developments. • Utilize the relationships between key data sets for superior strategizing. • Suitable for supporting your internal and external presentations with reliable high quality data and analysis • Gain a global perspective on the development of the market. • Report will be updated with the latest data and delivered to you within 3-5 working days of order. Scope Markets Covered: Blood Products; Anemia And Other Blood Disorder Drugs Companies MentionedNovo Nordisk A/S, Shire Plc, Bayer AG, Daiichi Sankyo Company, Limited, Biogen Inc. Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia. Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa Time series: Five years historic and forecast. Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, Hematology Drugs Indicators Comparison. Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments. Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

3. Hematology Hematology Drugs Characteristics Characteristics Drugs Market Market Hematology drugs market offers drugs, blood and blood products that are used for the treatment of diseases such as rare genetic disorders, anemia, and conditions related to sickle cell disease and other related diseases. Some of the major hematology drugs include Albumin, Epoetin, Zoladex, and Hyskon. The market numbers within this briefing are restricted to pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing. The hematology drugs industry is further classified as follows – Blood Products companies produce blood components such as Anemia And Other Blood Disorder Drugs companies produce drugs that can be used to In this report market value is defined as the revenues organizations earn by selling their goods and services within the specified market, based on the price at which they sell. Only goods and services traded between entities are included. The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.

4. Hematology Drugs Hematology Drugs Market Historic Growth Historic Growth Market The global hematology drugs market grew from $X billion in 2013 to $X billion in 2017 at a compound annual growth rate (CAGR) of X%. The chart and table below shows the year-on-year growth of the global hematology drugs market during 2013 – 2017. Drivers of the Market: Restraints on the Market:

5. Hematology Drugs Hematology Drugs Market Forecast Growth Forecast Growth Market The global hematology drugs market is expected to grow from $XX billion in 2017 to $50.8 billion in 2021 at a compound annual growth rate (CAGR) of XX%. Going forward, unhealthy lifestyle leading to anemia and coagulation disorders, along with increased longevity and the launch of pipeline drugs is set to drive the market for hematology drugs. The chart and table below shows the year-on-year growth of the global hematology drugs market during 2017 - 2021. Drivers of the Market: Restraints on the Market:

6. Hematology Drugs Hematology Drugs Market Segmentation Segmentation Market The chart and table below shows the split of the hematology drugs market in 2017. The total market value for hematology drugs was $X billion in 2017. The markets that are covered include Blood Products; Anemia And Other Blood Disorder Drugs. Blood Products was the X largest segment in the hematology drugs market with X% share of the market. The market value for the blood products was $X billion in 2017. Anemia And Other Blood Disorder Drugs made up around X% share of the market. The market value for the anemia and other blood disorder drugs was $X billion in 2017.

7. Hematology Drugs Hematology Drugs Market Regional And Country Analysis Regional And Country Analysis Market The Asia Pacific was the largest region in the hematology drugs market in 2017, hematology drugs for $X billion or X% market share. North America was the x largest region hematology drugs for $X billion or X% market share. Western Europe was the x largest region hematology drugs for $X billion or X% market share.

8. Hematology Drugs Hematology Drugs Market Competitive Landscape Competitive Landscape Market The leading competitors in the global hematology drugs market are Novo Nordisk A/S, Shire Plc, Bayer AG, Daiichi Sankyo Company Limited, Biogen Inc. The chart and table below displays the percentage market share of the top players in the hematology drugs market industry. Novo Nordisk A/S generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Shire Plc. generated revenues of $XX billion for the financial year 2016. Bayer AG generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Daiichi Sankyo Company, Limited generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year.

9. Biogen Inc. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Pfizer Inc. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Company Profile Novo Nordisk A/S Overview Novo Nordisk was the largest company in the hematology drug market with a XX% share of the market in 2017. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. It is a healthcare company involved in discovering, developing, manufacturing, and marketing of pharmaceutical products. Novo Nordisk markets and distributes its products through distributors and independent agents worldwide. Products and Services Novo Nordisk operates through following divisions – The Diabetes And Obesity Care division offers insulin The Biopharmaceuticals division offers products related to Strategy Novo Nordisk’s growth strategy is to expand its hematology business by developing new drugs for treatment of hematologic disorders. In June 2017, the Food and Drug Administration of the US approved Novo Nordisk’s Rebinyn coagulation treatment for the treatment of hemophilia B. Rebinyn, which can be used for treatment and control of bleeding disorders in patients with Financial Performance Novo Nordisk’s Haemophilia Biopharmaceuticals division, are and Norditropin involved sections hematology in its in drug

10. Shire Plc manufacturing, and generated revenues of DKK XX billion ($XX billion) for the financial year 2016, a XX% increase from the previous year. Overview Products and Services Strategy Financial Performance Bayer AG Overview Products and Services Strategy Financial Performance Daiichi Sankyo Company Limited Overview Products and Services Strategy Financial Performance Biogen Inc. Overview Products and Services Strategy Financial Performance